Autres langues ACADIA Pharmaceuticals Inc.

Actions

ACAD

US0042251084

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 25/04/2024			Varia. 5j.	Varia. 1 janv.
16,31 ^USD	-1,69 %		-4,45 %	-47,91 %

22/04	Acadia Pharmaceuticals Inc annonce que la présentation de drogue nouvelle de trofinetide pour le traitement du syndrome de Rett a été acceptée pour dépôt et examen prioritaire par Santé Canada	CI
17/04	ACADIA Pharmaceuticals Inc. présente de nouvelles données cliniques sur DAYBUE (trofinetide) lors de la réunion annuelle de l'American Academy of Neurology en 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024	24/04
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	23/04
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	22/04
Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	22/04
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	22/04
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	22/04
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19/04
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting	17/04
ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting	17/04
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development	02/04
ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development	02/04
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference	01/04
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing	28/03
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 15, 2024	18/03
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	15/03
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day	13/03
North American Morning Briefing : Stock Futures -2-	13/03
Sector Update: Health Care Stocks Gain Premarket Tuesday	12/03
Aktien New York Ausblick: Gewinne erwartet nach Inflationsdaten	12/03
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	12/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ACADIA Pharmaceuticals Inc.

Actions

ACAD

US0042251084

Autres langues

Filtres